Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

A single-patient case shows iopofosine I 131’s durable response, but broad claims lack data.

What the company is saying

Cellectar Biosciences highlights a case study of a 53-year-old woman with high-grade, double-hit diffuse large B-cell lymphoma who achieved a complete response lasting over eight years after a single 57.5 mCi dose of iopofosine I 131. The company frames this as evidence of the PDC platform’s ability to selectively target malignant cells and draws parallels to results seen in its Phase 2b CLOVER WaM study for relapsed/refractory Waldenström macroglobulinemia, though no quantitative data from that study are disclosed. CEO James Caruso and COO Jarrod Longcor both emphasize the durability and depth of response as indicative of broader potential across B-cell malignancies. The announcement stresses regulatory momentum, citing FDA Breakthrough, Orphan Drug, Rare Pediatric Drug, and Fast Track designations, as well as EMA PRIME status for iopofosine I 131. The company states it will begin dosing in a confirmatory Phase 3 WM study in Q1 2027 and aims to submit an accelerated approval application in the first half of 2027. The tone is confident and forward-looking, but the narrative generalizes from a single case and references other studies without presenting supporting efficacy data.

What the data suggests

The case study documents a single patient who, after four prior therapies and stem cell transplantation, received one dose of iopofosine I 131 on March 20, 2018. By Day 48, the patient achieved at least a partial response, and by Day 85, a complete response was confirmed, with the target lesion shrinking from 825 mm³ to 0 mm³. As of May 2026, more than eight years post-treatment, the patient has had no disease progression and required no further anticancer therapy. All hematologic toxicities resolved. No new quantitative data are provided for other pipeline assets or ongoing studies. The company lists multiple regulatory designations but does not disclose financials, operational metrics, or broader clinical efficacy rates. The evidence is robust for this single case but does not establish generalizable efficacy or commercial viability.

Analysis

The announcement is anchored by a compelling, well-documented case study showing a durable complete response in a single heavily pretreated DLBCL patient, with over eight years of progression-free survival. This is a realised, measurable outcome, and the clinical details are specific and credible. However, the broader narrative inflates the signal by extrapolating from this single case to platform-wide validation and by referencing efficacy in other studies without providing supporting data. Several forward-looking statements concern future trial milestones (Phase 3 initiation and FDA submission in 2027) and pipeline assets, but these are not paired with new clinical or financial results. The absence of financial or operational metrics means the announcement cannot be rated above weak_positive. The hype level is moderate due to language that generalises from a single case and references to 'compelling clinical activity' and 'strong preclinical data' without quantitative evidence.

Risk flags

• ●The announcement relies on a single-patient case study, which cannot be extrapolated to broader patient populations or predict Phase 3 outcomes. Single cases are susceptible to outlier effects and do not substitute for controlled trial data.
• ●No quantitative efficacy or safety data from ongoing Phase 2b or other studies are provided, limiting the ability to assess the consistency or magnitude of benefit across larger cohorts. This raises uncertainty about the reproducibility of results.
• ●Key clinical and regulatory milestones, including Phase 3 initiation and FDA submission, are not imminent and are subject to execution risk, including trial recruitment, data quality, and regulatory review outcomes.
• ●The company provides no financial data, cash runway, or operational metrics, leaving investors unable to evaluate funding sufficiency or capital needs ahead of long-dated milestones.

Bottom line

Cellectar’s announcement documents a remarkable eight-year complete response in a heavily pretreated DLBCL patient after a single dose of iopofosine I 131, with all toxicities resolving. While this outcome is clinically impressive, it is based on a single case and cannot be assumed to predict broader efficacy. The company references positive signals from other studies and regulatory momentum, but does not provide supporting data or financial disclosures. The next tangible catalysts—Phase 3 WM study dosing and an FDA submission—are not expected until 2027, leaving a long execution window and significant uncertainty. Investors should see this as an intriguing clinical anecdote, not yet a platform validation or commercial inflection point. The most important takeaway is that platform-wide claims remain unproven until supported by larger, controlled trials.

Announcement summary

(NASDAQ:CLRB) Cellectar Biosciences, Inc. reported results from a case study of a 53-year-old woman with high-grade, double-hit diffuse large B-cell lymphoma (DLBCL) who had received four prior lines of therapy and stem cell transplantation. The patient received a single dose of iopofosine I 131 (57.5 mCi) on March 20, 2018. By Day 48, the patient achieved a partial response or better, and by Day 85, a complete response was confirmed by both site investigators and sponsor assessment. The target lesion shrank from 825 mm³ at baseline to complete resolution (0 mm³) by Day 85. As of May 2026, more than eight years after the single infusion, the patient has experienced no disease progression and has required no additional anticancer therapy. Duration of response, progression-free survival, and time to next treatment remain ongoing and unreached at more than eight years. The patient experienced expected hematologic toxicities, including anemia, lymphopenia, thrombocytopenia, and neutropenia, all of which resolved. Cellectar plans to submit these findings for journal publication or presentation at a medical meeting. James Caruso, president and chief executive officer of Cellectar, stated that the results further validate the PDC platform's ability to selectively target malignant cells. The company is advancing its confirmatory Phase 3 study in Waldenström macroglobulinemia (WM) and expects to initiate patient dosing in the first quarter of 2027, with plans to submit an accelerated approval application to the U.S. Food and Drug Administration in the first half of 2027. The case study aligns with efficacy and durability observed in Cellectar's Phase 2b CLOVER WaM study in relapsed/refractory Waldenström macroglobulinemia, where iopofosine has generated durable responses in heavily pretreated patients, including those refractory to prior therapies. Jarrod Longcor, chief operating officer of Cellectar Biosciences, commented that the findings reinforce the compelling clinical activity observed in the Phase 2b CLOVER WaM study, including responses in patients refractory to Bruton’s Tyrosine Kinase inhibitors. Iopofosine I 131 is a novel phospholipid drug conjugate (PDC) designed to provide targeted delivery of iodine-131 directly to cancer cells and has been tested in Phase 2b trials for relapsed or refractory Waldenström Macroglobulinemia (WM), multiple myeloma (MM), and central nervous system (CNS) lymphoma. Iopofosine I 131 has also been tested in the CLOVER-2 Phase 1b study in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation. Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors such as triple negative breast (TNBC), lung, and colorectal cancer, currently being evaluated in a Phase 1b study for TNBC to determine the recommended dose for a subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth. Additionally, Cellectar is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Disagree with this article?